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Abstract
Background: Ciz1 promotes initiation of mammalian DNA replication and is present within nuclear matrix
associated DNA replication factories. Depletion of Ciz1 from normal and cancer cells restrains entry to S phase and
inhibits cell proliferation. Several alternative splicing events with putative functional consequences have been
identified and reported, but many more variants are predicted to exist based on publicly available mRNAs and
expressed sequence tags.
Methods: Here we report the development and validation of a custom exon and exon-junction microarray
focused on the human CIZ1 gene, capable of reproducible detection of differential splice-variant expression.
Results: Using a pair of paediatric cancer cell lines and a pool of eight normal lines as reference, the array
identified expected and novel CIZ1 splicing events. One novel variant (delta 8-12) that encodes a predicted protein
lacking key functional sites, was validated by quantitative RT-PCR and found to be over-represented in a range of
other cancer cell lines, and over half of a panel of primary lung tumours.
Conclusions: Expression of CIZ1 delta 8-12 appears to be restricted to cancer cells, and may therefore be a useful
novel biomarker
Background
Ciz1 (Cip1 interacting zinc-finger protein 1) is a nuclear
protein that appears to be encoded by 17 exons that
map to chromosome 9q34 in man (Unigene Hs.212395).
Ciz1 is expressed in a wide range of tissues [1] and con-
tains N-terminal polyglutamine repeats, 3 zinc finger
motifs, one matrin 3 domain at the C-terminal end, 2
putative nuclear localization signals and a number of
cyclin-dependent kinase phosphorylation sites and
cyclin-binding motifs [2]. Ciz1 was first identified
through its interaction with p21/Cip1 [3], a cyclin-
dependent kinase (CDK) inhibitor involved in regulation
of the cell cycle and in cellular differentiation. We iden-
tified Ciz1 in a cell-free system that reconstitutes initia-
tion of DNA replication, under the regulation of cyclin
A/CDK2 [4]. Using cell-free and cell-based approaches
we showed that Ciz1 stimulates initiation of DNA
replication in late G1 phase nuclei [5] and that it coop-
erate with cyclin E and A in order to execute its func-
tion in DNA replication [2]. Further detailed analysis
revealed that DNA replication activity resides in the
N-terminal half of Ciz1, while the protein becomes teth-
ered to non-chromatin nuclear matrix structures
through C-terminal sequences that play a role in its
localization to DNA replication factories [6]. Taken
together the data suggest that Ciz1 plays a linker role
between the DNA replication machinery and the sub-
nuclear structures that organize their function.
CIZ1 is a hormone-responsive gene [7,8] and is thought
to play a role in the development or progression of oestro-
gen responsive tumours. It has also been linked with cer-
tain paediatric cancers [1,9], where alternatively spliced
transcripts are prevalent. Similarly, inappropriate expres-
sion of alternatively spliced transcript has been reported to
occur in brain tissue from Alzheimer patients [10]. Pre-
viously, we surveyed over 600 CIZ1 expressed sequence
tags that map to the CIZ1 Unigene cluster [9], to overview
alternative splicing during development and disease. This
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highlighted three exons in the 5′ end of Ciz1 that are com-
monly alternatively spliced and potentially mis-spliced
under some circumstances, and suggested a range of other
rarer splicing events.
In this study our aim is to look at CIZ1 variant
expression in order to validate previously reported alter-
native splicing (AS) events, and to discover new ones.
We chose to use an exon junction array because com-
monly used methods for splicing analysis such as
RT-PCR, cDNA primer extension and nuclease protec-
tion mapping are extremely labour intensive for highly
spliced genes, particularly when analysis of a large num-
ber of samples is expected. Therefore, we have devel-
oped an exon junction-array focused on the human
CIZ1 gene that is capable of detecting all known
variants and hypothetical variants of CIZ1. We present
results generated with this exon array-tool, initially
using a pair of paediatric cancer cell lines. This identi-
fied several novel AS events including one cancer-
restricted novel variant that we chose to validate further.
The functional implications of expression of this variant
(which has partial deletion of exon 8 and exon 12 and
skipping of exon 9, 10 and 11) are discussed and poten-
tial applications highlighted.
Methods
Array and probe design
We designed oligonucleotide probes with extensive cov-
erage for CIZ1 mRNAs and predicted variants. These
include probes homologous to exons, observed junc-
tions, hypothetical junctions and retained intron
sequences (Fig. 1). The array also includes probes
homologous to other genes that either emerged from
our biochemical studies as Ciz1 interacting partners,
have roles in cell cycle predicted to interact with Ciz1
or are known to be involved in pathology of sporadic
cancers (additional file 1 Table S1). For 5′ untranslated
sequences we included probes that cover possible alter-
native first exons. These are defined as exon 1a (in
NCBI Reference Sequence: NM_012127.2 and
NM_001131015.1) and exon 1c (NM_001131017.1,
NM_001131018.1 and NM_001131016.1). Other alterna-
tively used exon 1 s were predicted by AceView (addi-
tional file 2 Figure S1) and confirmed by us when
searching CIZ1 EST transcript against the BLAT CIZ1
assembly [11]http://genome.ucsc.edu/, and designated
exon 1b and 1d (additional file 3 Figure S2). To our
knowledge inclusion of exon 1b and 1d has not been
verified by inclusion in a full-length human CIZ1
transcript.
To allow for a reasonable trade off between signal
intensity and specificity, we restricted length of the
probes to 40 nucleotides [12]. To increase specificity of
probes, interspersed repeats and low complexity DNA
sequences were masked (repeats have been replaced by
Ns) using repeat masker [13]http://www.repeatmasker.
org. The masked sequences were then searched for simi-
larity against BLAT and areas which showed significant
Figure 1 Schematic representation of the location of human CIZ1 probes, designed to detect expression of the most common
predicted exons, less common alternative exons, rare alternative exons containing intronic sequences, most common and observed
rare exon-junctions and a selection of hypothetical junctions. For junction probes between most common predicted exon, - indicates the
junction such as Ciz1ex2-ex3. For junction probes between less common predicted exons, such as Ciz1 exon 2 alternative 1 and exon 2
alternative 2, the probe designation will be defined as Ciz1-ex2a1-ex2a2. Probe sequences are given in additional file 1 Table S1.
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similarity were excluded. For junction probes, we
employed the sliding window method where the 40 nt
can slide across the target junction to allow for near
similarity in melting temperatures [12]. Probes were
then searched for similarity using BLAST non-redun-
dant database with expectation value of 10 http://blast.
ncbi.nlm.nih.gov/Blast.cgi[14]. Probes with more than 20
contiguous identical bases to non-self transcript were
excluded. For all probes, exclusion criteria were set to
include those with hairpin structures with stem exceed-
ing 9 bases as well as those with self complementarities
of more than 6 bases [15]. However, due to the con-
straints of the exon junctions, these parameters could
not be applied to all probes. As the CIZ1 gene is rich in
GCs, the target Tm was set not to exceed 85°C (addi-
tional file 1, Table S1). Probes were synthesized by
Operon Biotechnologies GmbH, Cologne, Germany. The
oligonucleotide probes were printed on Nexterion Slides
E (Schott) using a QArrayMini (Genetix) as follows:
5 replicates were printed for each probe in a random
pattern including buffer as negative controls. Two slides
from each batch of printing were analysed for spot qual-
ity using Ribogreen (Molecular Probes). Prior to hybridi-
sation, each slide was washed at room temperature as
follows: 1 × 5 min in 0.1% Triton X-100, 2 × 2 min in
1 mM HCL, 1 × 10 min in 100 mM KCL. Slides were
subsequently blocked by incubation in 1 × Nexterion®
Blocking E (Schott) for 15 min and then dried by centri-
fugation. Microarray data associated with this paper was
submitted to ArrayExpress (accession: E-MEXP-2331)
with the experiment name ‘Differential detection of
alternatively spliced variants of Ciz1′.
Cell culture and RNA extraction
A pool of eight stable cell lines of non-tumour origin
were used as a reference control, (IMR90, WI38,
HEK293, MRC5, HFL1, ASF-4-1, TIG-2M-30 and
RPM1788, Table 1). Cell lines were obtained from the
European Collection of Cell Cultures (ECACC) and the
Japanese Collection of Research Bioresources (JCRB).
Cells were cultured exactly as recommended. Total
RNA was extracted using TRIZOL as recommended by
the manufacturer (Invitrogen). RNA concentration was
quantified using nanodrop spectrophotometer and equal
concentrations from each of the eight samples were
pooled together. SKNMC and TC466 Ewing tumour cell
lines were used as test samples to validate the array and
were handled as described previously [9].
Preparation and labeling of templates
20 μg of pooled RNA reference control or test samples
(SKNMC and TTC466) were reversed transcribed as
described and labeled using Invitrogen protocol (Super-
Script ™Plus Indirect cDNA labeling System). Labelled
reference and test sample (20 μl each) were combined
in an amber tube, mixed and heated at 99°C for three
minutes before hybridization.
Prehybridization and Hybridization
Prior to hybridization slides were prepared as mentioned
previously. Hybridization was carried out in a final
volume of 40 μl in Corning hybridization chambers, in a
water bath at 42°C for 16-24 h. Microarray slides were
then washed twice in 1× SSC with 0.1% SDS for five
minutes, once in 0.1× SSC with 0.1% SDS for 5 minutes
and a final wash in 0.05× SSC for five minutes. Slides
were transferred to a centrifuge tray and spun for three
minutes at 2000 rpm at room temperature to dry.
Image acquisition and data analysis
Slides were scanned using GenePix 4000B microarray
scanner and images were analyzed using GenePix soft-
ware where a grid layout was applied to the features.
Data analysis was performed using ArrayAssist software
where background correction was done using fore-
ground-background (FG-BG). Features with signal inten-
sities less than 2.5 fold of the mean background signal
were removed, and ratios were normalized using house-
keeping gene normalization [16] and were averaged and
log transformed.
Reverse-Transcriptase PCR
cDNA was generated using superscript III Synthesis Kit
according to manufacturer’s instructions (Invitrogen).
Normalization of input cDNA was done using Actin for-
ward (5′CAACCGCGAGAAGATGACC3′) and reverse
primers (5′TCCAGGGCGACGTAGCA CA3′) as endo-
genous control. For CIZ1 sequences spanning exon 8 to
exon 13, primers Ciz1-ex8F (5′CTCCAGGGCAGTTA-
CAGGAC3′) and Ciz1-ex13R2 (5′TGCGAGGGGTT
TTGAAGTAG3′) were PCR amplified at 58°C annealing
temperature using phusion high-fidelity DNA polymerase
Table 1 Cell lines used in this analysis
Cell line Derivation Reference
TTC466 Ewings Tumour [23]
SKNMC PNET [24]
H727 Human bronchial carcinoid [25]
IMR90 Human embryonic lung [26]
WI38 Human embryonic lung [27]
HEK293 Human embryonic kidney [28]
MRC5 Human embryonic lung [29]
HFL1 Human embryonic lung [30]
ASF-4-1 Skin fibroblast from upper arm [31]
RPMI 1788 normal blood, IgM secreting [32]
TIG-2M-30 muscle, normal diploid fibroblast [33]
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(Finnzymes). For the variant with partial deletion of exon 8
and exon 12 and skipping of exon 9, 10 and 11, splice junc-
tion specific primers were used. Forward primer, Ciz1-
jex8-ex12F (5′CTCCAGGGCAGTTACAGGAC3′) and
reverse primer hCiz1-Jex13-ex14R (5′CTCAAGCGACTT-
CAGCTCCT3′) were PCR amplified at 60°C annealing
temperature using Taq polymerase (New England Biolab
(NEB). For alternative exon 1 s, forward primers Ciz1-
ex1b (5′CAGACGGACCTTGGT CTCC3′), Ciz1-exon 1c
(5′GCGACTTGAGCGTTGAGG3′) and Ciz1-ex1d (5′
GGCGG TGGTGGAGAGAAG3′) were all combined with
reverse primer Ciz1-ex5R (5′CGATTGG GGGTGGTA-
GAGG3′) in separate reactions. Taq polymerase (NEB)
was used for amplification at annealing temperatures of
60°C, 62°C and 56°C respectively.
Quantitative Real-Time PCR
Reactions were carried out using an ABI 7000, initial
incubation at 95°C/10 min, followed by 95°C/15 sec and
1 min at 60°C for 40 cycles. Triplicate reactions were
carried out in 96-well plates in a 25 μl reaction volume
containing 12.5 μl cyber green Master Mix (Applied
Biosystems), 20 ng cDNA and 200 nM each of hCiz1-
Jex8-ex12F forward and hCiz1-Jex13-ex14R reverse. Pri-
mers used for normalization include, Actin F and Actin
R as well as GAPDH forward (5′ATCCCATCAC-
CATCTTCCAGG3′) and reverse (5′GCATC GCC
CCACTTGATTTTG 3′).
Results and discussion
CIZ1 is represented by 865 GenBank entries that map to
Unigene Build number 224, cluster Hs.212395. These
mRNAs and ESTs were aligned cooperatively by Ace-
View [17] to exclude redundancies producing 27 mRNA
assemblies (additional file 2 Figure S1 1). These were
then aligned to the gene sequence and exon boundaries
and splice junctions identified. CIZ1 probes were
designed from constitutive regions, alternative regions
and observed exon-exon splice junctions. To allow for
discovery of novel alternative splicing events, we also
designed probes representing hypothetical exon-exon
junctions. The array is designed to survey overall CIZ1
alternative splicing in different tissues, diseases and
developmental stages, with the aim of substantiating
observed alternative splicing features and identifying
novel alternative splicing events. Here we discuss initial
array results on the SKNMC PNET and TTC466 Ewing
tumour cell lines.
Analysis of the technical replicates in this study
showed that out of 26 exon probes the data was consis-
tent and informative for 24 probes (92%) for the
SKNMC cell line and 23 probes (88.5%) for TTC466
cell line. Data was not obtained for the CIZ1 exon 17
probe in either cell line suggesting a problem with the
probe. For the remaining 3 (Fig. 2A, B), their failure was
cell-line specific, possibly reflecting severe under or over
expression outside the detection parameters of this ana-
lysis. For the 73 CIZ1 junction probes used here repro-
ducible data was not available for 5 junctions observed
in the EST databases and 14 that were rare or hypothe-
tical junctions for SKNMC cells (Fig. 3). Similarly for
TTC466, of the 73 junction probes, data was not avail-
able for 4 observed junctions and 17 rare or hypotheti-
cal junctions (Fig. 4). Three of the observed and 11 of
the rare or hypothetical junctions were common to both
cell lines. We consider these figures to be within the
expected range due to the constraints inherent in
designing probes for exon junctions, coupled with the
fact that some of the hypothetical junctions may never
exist in reality. Of greater interest is the hypothetical
junctions that were consistently represented in the tran-
scriptome of these two cell lines. These are ex1ca1-ex2,
ex1c-ex2a2, ex1c-ex4, ex1c-ex6, ex2-ex7 and ex7-ex10
(depicted graphically in additional file 3 Figure S2), indi-
cating an unanticipated level of AS around untranslated
exons 1 and 2.
Analysis of 3 technical replicates for Ewings tumour
cell line SKNMC showed that CIZ1 exon 1b is up-regu-
lated and CIZ1 intron 12 (alternative exon) is down
regulated relative to the reference template, although
both fall only just within inclusion criteria of 1.5 fold
change. When compared to 2 further biological repli-
cates (isolated from separate population of SKNMC
cells), neither probe proved to be consistently different
to the reference template (Table 2 and Fig. 2A). How-
ever similar analysis of cell line TTC466 also indicated
differential expression of the alternative exon 1s. In fact
CIZ1 exon 1c was considerably up-regulated in all three
biological replicates (Table 3), with an SEM of 0.355135
between the three technical replicates (Fig. 2B). More-
over among the exon 1c-junction probes, 4 were consis-
tently up-regulated relative to the reference control in
all 3 biological replicates and 3 of these were among the
top 4 ranked products [18] (additional file 4 Table S2).
This analysis revealed splicing of exon 1c onto exon 2
(variant 2), exon 4 and exon 6 and splicing of alternative
exon 1c (1ca1) onto exon 2 (Table 3 and Fig. 3).
Other genes in this study that were overrepresented in
all technical and biological replicates were RB1 and
VPS72 for SKNMCS cell line, and CDC2, CDC6,
TNRC9 and DDX17 in TTC466 cells (additional files 6
and 7 Tables S4-S13). VPS72 is an interacting partner of
EWSR1 gene [19]. RB1, CDC2 and CDC6 may share the
same pathways as CIZ1 gene. Expression of these genes
needs to be validated and their function with regard to
Ciz1 further analysed.
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Expression of alternative exon 1s
We surveyed CIZ1 ESTs using BLAT [11] to review alter-
native usage of exon 1. This showed that CIZ1 exon 1c is
supported by 4mRNAs and 139 ESTs which exceeds by
far the number of mRNAs and ESTs supporting other
exon 1 s. The second most common is exon 1b supported
by 16 ESTs. This analysis might not reflect the true nature
of exon 1 usage due to possible bias towards 3′ exons. In
this study, we detected over-expression of the novel alter-
native exon 1b in technical replicates of both SKNMC and
TTC466 cell lines (Tables 2 and 3), however no change
was observed in biological replicates of the two cell lines.
On the other hand for exon 1c, array results showed
consistent up-regulation in TTC466 cell line as well as the
junctions of exon 1c and other exons (2, 4 and 6). Taken
together these results suggest that exon 1c is the most
widely used alternative exon 1 for the CIZ1 gene. Protein
translation for alternative usage of exon 1 s on the back-
ground of full length Ciz1 showed that exon 1c and 1d
would encode the same protein. On the other hand trans-
lation for exon 1b showed there are two additional pre-
dicted methionines upstream of the usual predicted
methionine in exon 2, adding an extra 28 amino-acids to
the N-terminal end of the Ciz Protein. 5′ UTR selection
has been shown to affect alternative splicing of down-
stream exons. For example, for oestrogen receptor b it has
Figure 2 Expression of CIZ1 in paediatric cancer cell lines revealed by hybridization to CIZ1 exon probes. A: CIZ1 exon expression in
primitive neural ectodermal tumour (PNET) cell line SKNMC. B: CIZ1 exon expression in Ewing tumour TTC466 cell line. Plots show the average
of three technical replicates expressed as log2 of the ratio between signal generated by the test sample and signal generated by reference RNA.
Change is considered to be significant where this fall outside 0.58 or -0.58 and therefore exceed 1.5 fold relative to control. Bars indicating SEM
are shown for probes included by these selection criteria. No reliable data was achieved for probes indicated with a grey dot.
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Figure 3 Expression of CIZ1 in paediatric cancer cell lines revealed by hybridization to CIZ1 exon-junction probes for SKNMC PNET
cell line. Plots show the average of three technical replicates expressed as log2 of the ratio between signal generated by the test sample and
signal generated by reference RNA. Change is considered to be significant where this fall outside 0.58 or -0.58 and therefore exceed 1.5 fold
relative to control. Bars indicating SEM are shown for probes included by these selection criteria. No reliable data was achieved for probes
indicated with a grey dot.
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Figure 4 Expression of CIZ1 in paediatric cancer cell lines revealed by hybridization to CIZ1 exon-junction probes for TTC466 Ewing
tumour. Plots show the average of three technical replicates expressed as log2 of the ratio between signal generated by the test sample and
signal generated by reference RNA. Change is considered to be significant where this fall outside 0.58 or -0.58 and therefore exceed 1.5 fold
relative to control. Bars indicating SEM are shown for probes included by these selection criteria. No reliable data was achieved for probes
indicated with a grey dot.
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been reported that alternative 5′ UTR influences splicing
and may alter protein function [20]. Furthermore, inap-
propriate expression of 5′ UTRs has been implicated in
carcinogenesis in the case of BRCA1 [21] and Mdm2 [22].
The functional significance of CIZ1 alternative exon 1
expression requires further investigation, however their
expression may play a role in specifying alternative splicing
of the rest of the CIZ1 gene.
Exclusion of exon 4
Previously, we showed that an alternatively spliced
human CIZ1 variant, with deletion of exon 4 (ΔE4), is
mis-expressed as a consequence of intronic mutation in
Ewings Tumour (ET) cell lines, including the two cell
lines used here [9]. However, skipping of exon 4 was not
reproducibly detected in either cell line. This is most
likely due to constraint inherent in the sequence of
Table 2 Summary of CIZ1 alternative splicing in SKNMC cell line
SKNMC exon probes Average of 3 technical replicates (B1) Biological replicate 2 Biological replicate 3
Ciz1-ex1b2 + = =
Ciz1-intron 12 - = -
SKNMC junction probes
Ciz1-ex8a0-ex12a1 + + +
Ciz1-ex8af2-ex15 + + =
Ciz1-ex12-ex13 + + +
Ciz1-ex15-ex16 - = =
Three independent RNA isolates from proliferating SKNMC cell (Biological replicates, B1, B2 and B3) were analysed on individual arrays, with one isolate
undergoing analysis in triplicate (technical replicate, T1, T2 and T3 shown in Fig. 2A and 3). Probes that are up or down regulated more that 1.5 fold and who’s
SEM indicate agreement between three technical replicates are shown. Results for these probes derived from the two further biological replicates (replicate 2
and replicate 3) are also shown. + indicates significantly up-regulated, - indicates significantly down-regulated and = indicates no significant change. Significance
is taken to be a change that is ≥ 1.5 fold compared to control RNA. For paediatric cancer cell line SKNMC, expression of two probes was consistently and
significantly altered compared to control samples, these are Ciz1-ex8a0-ex12a1 and Ciz1-ex12-ex13. Raw data is given in Additional file 5, tables S4-S8.
Table 3 Summary of CIZ1 alternative splicing in TTC466 Ewing cell line






Ciz1-ex1 + nd =
Ciz1-ex1b1 + = =
Ciz1-ex1c + + +
Ciz1-ex2 + = =
Ciz1-ex3 + + +
TTC466 junction probes
Ciz1-ex1ca1-ex2 + + +
Ciz1-ex1c-ex2a2 + + +
Ciz1-ex1c-ex4 + + +
Ciz1-ex1c-ex6 + + +
Ciz1-ex2-ex7-a + + +
Ciz1-ex2-ex7-b + = =
Ciz1-ex4-ex5 + + +
Ciz1-ex7-ex10 + + +
Ciz1-ex8a0-ex12a1 - nd _
Ciz1-ex9-ex10 + + +
Ciz1-ex13-ex14 + = =
Ciz1-ex15-ex16 _ = =
Ciz1-ex16-ex17 + = =
Three independent RNA isolates from proliferating TTC466 cells (Biological replicates, B1, B2 and B3) were analysed on individual arrays, with one isolate
undergoing analysis in triplicate (technical replicate, T1, T2 and T3). Probes that are up or down regulated more that 1.5 fold and who’s SEM indicate agreement
between three technical replicates are shown. Results for these probes derived from the two further biological replicates (replicate 2 and replicate 3) are also
shown. + indicates significantly up-regulated, - indicates significantly down-regulated and = indicate no significant change. For paediatric cancer cell line TTC466,
expression of 2 exon probes was consistently and significantly altered compared to control samples, these are Ciz1-ex1c and Ciz1-ex3. For exon junction probes
a total of 8 probes met all our selection criteria. These are Ciz1-ex1ca1-ex2, Ciz1-ex1c-ex2a2, Ciz1-ex1c-ex4, Ciz1-ex1c-ex6, Ciz1-ex2-ex7-a, Ciz1-ex4-ex5, Ciz1-ex7-
ex10 and Ciz1-ex9-ex10. Raw data is given in Additional file 6, tables S9-S13.
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CIZ1 junction exon 3-exon 5. Thus, this approach is not
suitable for further investigation of alternative splicing at
this site.
A novel cancer-associated variant
In addition to extensive AS of exon 1c , for TTC4666
cells a further 9 probes were significantly under or over
represented in 3 technical replicates compared to the
reference control, and four of these (2-7a, 4-5, 7-10,
9-10) were reproducibly detected in 2 further biological
replicates. We were most interested in one probe (8a0-
12a1) that is down-regulated in 3 of 3 technical repli-
cates and 2 of 3 biological replicates in TTC466 cells,
because the same probe is up-regulated in all replicate
experiments carried out with SKNMC cells. This is the
only probe that is significantly altered in both cell lines,
albeit upregulated in one and down regulated in the
other. This probe indicates expression of a CIZ1 splice
variant with partial deletion of exon 8 and 12 and skip-
ping of exon 9, 10 and 11, and is the top one of 4 ranked
products for SKNMC cells (additional file 4 Table S2).
To further investigate alternative splicing between
exon 8 and 12 in human CIZ1 (Fig. 5A), we used RT-
PCR from exon 8 (forward primer 8F) coupled with a
reverse primer in exon 13 (13R). Results showed 3 tran-
scripts in Ewings tumour cell lines and also in a third
Figure 5 Detection of over expressed CIZ1 spliced variants in cancer cell lines. A: Schematic representation of CIZ1 exon 8 to exon 13 and
the primers (Ciz1-ex8F-Ciz1-ex13R) used for amplification. Schematics I-III corresponds to the 3 bands seen in Fig. 5B (upper panel) which were
verified by sequencing. Schematic I represents full length exon 8-13, II shows partial deletion of exon 8 and III shows partial deletion of exon 8
and skipping of exon 9. Schematic IV indicates primers used to amplify the product shown in Fig. 5B (middle panel) and in Fig. 5C and D. B:
Upper, RT-PCR using the primer pair Ciz1-ex8F and Ciz1-ex13 R. Middle, RT-PCR using variant specific primers (Ciz1-jex8-ex12F - Ciz1-jex13-ex14R).
Bottom, actin primers were used for normalization. The panel includes three normal cell lines (HFL1, ASF and TIG) and three cancer cell lines
TTC466, SKNMC and H727). Stars indicate sequenced bands. C: Validation of microarray result for exon 8-12 with SKNMC and TTC466. Histogram
shows average quantitative PCR result for 3 replicates with SEM. Results were normalised to Actin levels and calibrated to pooled reference RNA
(8 normal cell lines including, IMR90, WI38, HEK293, MRC5, HFL1, ASF-4-1, TIG-2M-30 and RPM1788), as used in the microarray experiment. D:
Quantitative PCR with Ciz1 splice variant specific primers (Ciz1-jex8-ex12F and Ciz1-jex13-ex14R). The panel includes lung (SBC2, SBC5 and H727),
cervix (Hela), and Urothelial cancer cell lines (RT112, RT4 and EJ). Normal cell lines were also included (HFL and TIG) as well as the reference
poole RNA, which was used as calibrator. Results were normalized to GAPDH.
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cancer cell line H727 (human lung carcinoid). Three
products of the same mobility were detectable in 3 nor-
mal cell lines, but at considerably lower levels for the
smaller of the three (Fig. 5B, upper). Thus, these pro-
ducts are over-expressed in cancer cell lines. Sequencing
revealed the upper band (1344bp) to be the expected
CIZ1 full-length sequence (Reference sequence
NM_0121276.2, Fig. 5A), the middle band to lack
sequences internal to exon 8 (168 bp) and the lower
band to lack this region plus the whole of exon 9 (1054
bp). Taking NM_012127.2 as a reference sequence the
exon 9 deletion is described as c.1338_1505del168 and
exon 9 skipping as r.1702_1823del. Despite its preva-
lence in the cancer cell lines we studied, to our knowl-
edge, this is the first time this variant has been reported.
Neither of these events is represented by probes in our
array. Notably, the variant detected by our array that
splices exon 8 to exon 12 (c1038_2218del1181) was
barely detectable by this analysis. Therefore in order to
quantify its expression we designed specific primers
Ciz1-jex8-ex12F-Ciz1-jex13-ex14R (Fig. 5A). Results
showed increased expression in SKNMC cells compared
to 3 normal cell lines (HFL, ASF and TIG) and compar-
able expression in TTC466 cells (Fig. 5B, middle). The
165 bp product was sequenced, verified for SKNMC and
TTC466 and found to be as expected. Similar results
were obtained by quantitative real time PCR after nor-
malisation to actin levels and calibration to the pooled
reference RNA used in the arrays. As expected, results
showed significant over expression for this variant (exon
8-exon 12) in SKNMC and slight down-regulation in
TTC466 cell line (Fig. 5C), validating results obtained by
array analysis. Quantitative detection of this apparently
cancer-associated variant was extended to cover other
cancer cell lines derived from lung (SBC2, SBC5 and
H727), cervix (Hela) and urothelial cells (RT112, RT4
and EJ). Two individual normal cell lines HFL and TIG,
as well as the pooled reference RNA were included as
controls. Significant (greater than 2 fold) over- expres-
sion was detected in four of the 7 cancer cell lines (Fig.
5D). Furthermore, using Tissue Scan lung cancer array
HLRT504 (Origene), we performed quantitative real-
time PCR on cDNA obtained from 48 tissues. Results
showed significantly elevated levels of this CIZ1 splice
variant in 13 tumour samples compared to the matched
paired normal controls (Fig. 6). Thus, the data indicate
that exclusion of exon 9, 10, 11 and part of exon 8 and
exon 12 is a recurrent event in cancer cells. This variant
(c1038_2218del1181) lacks sequences that encode motifs
that are important for the function of Ciz1 in DNA
replication. Bioinformatic analysis revealed that the
excluded sequence encodes as many as 6 putative CDK
phosphorylation sites and 2 cyclin interaction sites (CY
motifs). Notably sequences encoded by exon 9 engage in
sequential interaction with cyclin E and A, and support
functional cooperation with cyclinA/CDK2 driving
initiation of DNA replication in vitro [2]. This analysis
was carried out with murine Ciz1 protein which is 64%
homologous at the protein level to human Ciz1 in this
region (exon 8-12). As the human variant described here
Figure 6 Quantitative PCR with CIZ1 splice variant specific primers (Ciz1-jex8-ex12F and Ciz1-jex13-ex14R) in Lung cancer. The lung
cancer Tissue Scan cDNA array (HLRT504, Origene) contains matched pair sets of 48 tissues covering four disease stages and normal tissues.
Each pair set is calibrated to its normal tissue and results were normalized to Actin. Grey columns indicates tumour and white columns indicates
paired normal tissue.
Rahman et al. BMC Cancer 2010, 10:482
http://www.biomedcentral.com/1471-2407/10/482
Page 10 of 12
is lacking these sequences our extrapolation is that it
will not be active in DNA replication, despite most
likely retaining down-stream sequences that anchor Ciz1
to the nuclear matrix [6]. Although further functional
analyses are needed to understand the impact that
expression of this variant has on DNA replication, these
data suggest it may interfere with the normal function
of Ciz1.
Conclusion
Expression of variant 8a0-12a1 that is restricted to can-
cer cells may offer a useful marker for their detection.
Furthermore, because siRNA depletion of Ciz1 has been
shown to delay S phase entry and restrain cell prolifera-
tion [5], selective inhibition of CIZ1 variants have
potential to offer selective restraint of those cell that
express them. Thus variant 8a0-12a1 has potential appli-
cation as a selective therapeutic target in some lung can-
cer patients.
Additional material
Additional file 1: Table S1. Probe sequences.
Additional file 2: Figure S1. Schematic representation of predicted
human Ciz1 alternatively spliced transcripts assembled by AceView from
865 mRNA and ESTs submitted to GenBank [17]. Blue lines represent
exons, black represent introns, yellow represent 5’ or 3’ untranslated
regions and * represent non canonical exon-intron boundaries.
Alternative transcript assemblies were designated, B, A, E, F, G, H, I, J, K, L,
M, P, Q, R, S, V, W, Y, Z, 27, 28, 29, 30, 31 and 32 by AceView.
Additional file 3: Figure S2. Observed and hypothetical exon-junctions
generated by alternative splicing of Ciz1 alternative exon 1 s (ex 1a, ex
1b, ex 1c and ex 1d). Common exons are indicated by labelled boxes
and less common alternative exons by solid black boxes. Observed and
hypothetical junctions are indicated by black and grey broken lines
respectively. Splicing events that are over represented in TTC466 are
indicated by solid lines. Sequences at 3’ end of alternative exon 1 s are
given in additional file 7 Table S14.
Additional file 4: Table S2. Ranked product, top 4 up-regulated probes
in technical replicates of SKNMC. Table S3 Ranked product, top 4 up-
regulated probes in technical replicates of TTC466.
Additional file 5: Table S4. microarray result for SKNMC technical
replicate 1 (T1). Table S5 microarray result for SKNMC technical replicate
2 (T2). Table S6 microarray result for SKNMC technical replicate 3 (T3).
Table S7 microarray result for SKNMC biological replicate 2 (B2). Table
S8 microarray result for SKNMC biological replicate 3 (B3).
Additional file 6: Table S9. microarray result for TTC466 technical
replicate 1 (T1). Table S10 microarray result for TTC466 technical
replicate 2 (T2). Table S11 microarray result for TTC466 technical
replicate 3 (T3). Table S12 microarray result for TTC466 biological
replicate 2 (B2). Table S13 microarray result for TTC466 biological
replicate 3 (B3).
Additional file 7: Table S14. Sequences of alternative exon 1 (3’ end).
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